KAHR Bio is a clinical-stage biotechnology company based in Modi’in, Israel that creates dual-targeting fusion protein therapeutics designed to activate both the innate and adaptive immune systems within the tumor microenvironment. Its lead candidate, DSP107, is a first-in-class bispecific CD47×4-1BB T-cell engager that anchors to CD47-expressing tumor cells while delivering a potent 4-1BB co-stimulatory signal to recruit and activate cytotoxic T cells. Across more than 130 treated patients, DSP107 has shown a favorable safety and tolerability profile. In a Phase 2a study of heavily pre-treated metastatic microsatellite stable colorectal cancer (MSS-CRC), DSP107 combined with atezolizumab achieved a 17.5-month median overall survival, outperforming the 6.4–10.8 months generally seen with approved therapies, even though 75% of patients had liver metastases. Encouraged by these data, the company has launched a randomized, controlled Phase 2b trial comparing DSP107 plus atezolizumab to fruquintinib in fourth-line MSS-CRC, with interim results expected in late 2026 and topline data in the second half of 2027. Proceeds from its latest financing and an accompanying debt facility are intended to fully fund this Phase 2b program and other R&D activities.

Total raised

$62M

Funding rounds

4

Latest round

Equity

Latest activity

Jan 2026